LIGAND-AI is a flagship project of the Target 2035 initiative, funded by the Innovative Health Initiative, a public-private partnership (PPP) between the European Union and the European life science ...
Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 2:30 PM ESTCompany ParticipantsJacob Chacko - ...
InvestorsHub on MSN
Entera Bio names former Pfizer executive Geno Germano as board chair
Entera Bio Ltd. (NASDAQ:ENTX) has appointed seasoned pharmaceutical executive Geno J. Germano as Chairman of the Board, ...
Men’s Health Network debuts “My Cancer, My Plan” Podcast to help men navigate diagnosis, treatment decisions, and ...
Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.
America’s drug safety agency declined to review a next-gen flu vaccine that uses the same tech as the coronavirus shots ...
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical ...
The FDA is considering expanding approval of Hympavzi to cover all people with hemophilia A or B ages 6 and older.
The vaccine maker’s shots involve the successful Covid vaccines’ RNA technology. Health Secretary Robert F. Kennedy Jr. has ...
Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that its Board of Directors has appointed ...
Pfizer (PFE) stock hold rating: 2026 patent cliff, falling Covid sales, GLP-1 obesity timeline, and M&A integration risks—read the outlook now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results